VanEck Pharmaceutical ETF
PPH
148 hedge funds and large institutions have $680M invested in VanEck Pharmaceutical ETF in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 49 increasing their positions, 55 reducing their positions, and 16 closing their positions.
584% more call options, than puts
Call options by funds: $3.14M | Put options by funds: $459K
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
12.43% more ownership
Funds ownership: 60.82% → 73.25% (+12%)
1% more funds holding
Funds holding: 147 → 148 (+1)
11% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 55
14% less capital invested
Capital invested by funds: $789M → $680M (-$109M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$88M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$47.9M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.4M |
| 4 |
Goldman Sachs
New York
|
+$20M |
| 5 |
Citigroup
New York
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$83.7M |
| 2 |
BCIM
British Columbia Investment Management
Victoria,
British Columbia, Canada
|
-$56.6M |
| 3 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
-$55.2M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$28.3M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$27.5M |
PPH Hedge Fund Activity: Q2 2026 in Review
148 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2026, worth a combined $680M — down 14% from $789M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PPH positions and 16 closed out — a net gain of 5 holders — while 49 added to existing stakes and 55 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $88M. The largest seller was Jane Street, cutting an estimated $83.7M.
- 148 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2026, up from 147 in Q1 2026.
- Funds reported $680M of VanEck Pharmaceutical ETF stock for Q2 2026, down 14% quarter-over-quarter.
- 21 funds opened new VanEck Pharmaceutical ETF positions in Q2 2026 and 16 closed out, a net change of +5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2026 was Morgan Stanley, an estimated $88M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2026 was Jane Street, an estimated $83.7M sold.
Based on aggregated 13F filings for Q2 2026.